Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9844016 | 0.90 | MITF (0.55) | MITFSLC6A4SLC6A3SLC6A2CA1 | |
| SCHEMBL5160892 | 0.86 | SLC6A4 (0.57) | MITFSLC6A4SLC6A3SLC6A2CA1 | |
| SCHEMBL2116076 | 0.85 | TDP1 (0.44) | MITFSLC6A4SLC6A3SLC6A2CA1 | |
| SCHEMBL27629296 | 0.85 | TDP1 (0.51) | MITFSLC6A4SLC6A3SLC6A2CA1 | |
| SCHEMBL27784843 | 0.81 | SLC6A2 (0.61) | MITFSLC6A4SLC6A3SLC6A2CA1 | |
| SCHEMBL16908331 | 0.81 | CA1 (0.55) | MITFSLC6A4SLC6A3SLC6A2CA1 | |
| SCHEMBL6936570 | 0.80 | SLC6A2 (0.63) | MITFSLC6A4SLC6A3SLC6A2CA1 | |
| SCHEMBL27505917 | 0.80 | SLC6A2 (0.63) | MITFSLC6A4SLC6A3SLC6A2CA1 | |
| SCHEMBL1415727 | 0.80 | SLC6A2 (0.63) | MITFSLC6A4SLC6A3SLC6A2CA1 | |
| SCHEMBL8654796 | 0.78 | MITF (0.57) | MITFSLC6A4SLC6A3SLC6A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388003-B1 | Colchicine derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3207929-B1 | COLCHICINE DERIVATIVES FOR THE TREATMENT OF CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3207929-A2 | COLCHICINE DERIVATIVES | California Pacific Medical Center (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-1617843-B1 | COLCHICINE DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-1643987-B1 | PODOPHYLLOTOXIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2016-11-30 | — | — | EP | disclosed |
| US-8158809-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2388003-A2 | Colchicine derivatives | California Pacific Medical Center (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | Sutter West Bay Hospitals, dba California Pacific Medical Center and Catholic Healthcare West | 2009-12-03 | — | — | US | disclosed |
| US-7605262-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080113941-A1 | Podophyllotoxin Derivatives | CALIFORNIA PACIFIC MEDICAL CENTER | 2008-05-15 | — | — | US | disclosed |
| US-20050004169-A1 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2005-01-06 | — | — | US | disclosed |
| US-6825207-B2 | ANTICANCER AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | disclosed |
| US-6825236-B2 | ACTIVE AGAINST TUMORS IN MICE AND ARE GENERALLY WELL TOLERATED | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | disclosed |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-10-14 | — | — | US | disclosed |
| CN-1511159-A | Nitrogen-based camptothecin derivatives | ����������̫ƽ��ҽѧ���� | 2004-07-07 | — | — | CN | disclosed |
| US-20040063740-A1 | For treatment of cancer | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-04-01 | — | — | US | disclosed |
| WO-2003101998-A1 | NITROGEN-BASED HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-04-17 | — | — | US | disclosed |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-02-13 | — | — | US | disclosed |
| US-6403604-B1 | ANTITUMOR | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063740-A1 | For treatment of cancer | MGMT, PAICS, DCK | MITF 3192/4885SLC6A4 1703/4885SLC6A3 4114/4885 |
| US-20080113941-A1 | Podophyllotoxin Derivatives | APEH, DAGLA, DPY30 | MITF 2242/4885SLC6A4 2433/4885SLC6A3 3543/4885 |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | MITF 3416/4885SLC6A4 2684/4885SLC6A3 3084/4885 |
| US-20050004169-A1 | Podophyllotoxin derivatives | APEH, DAGLA, DPY30 | MITF 2242/4885SLC6A4 2433/4885SLC6A3 3543/4885 |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, NAP1L4 | MITF 1039/4885SLC6A4 1929/4885SLC6A3 3663/4885 |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | APEH, DAGLA, DPY30 | MITF 2242/4885SLC6A4 2433/4885SLC6A3 3543/4885 |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | MITF 3416/4885SLC6A4 2684/4885SLC6A3 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.